Serum level of interleukin-10 with its gene polymorphism can be predictors of response to treatment in Egyptian patients with chronic hepatitis C virus

Egyptian Journal of Medical Human Genetics

Volumn 14, Issue 3, 2013, Pages 227-233

  Bassat, Hanan El ^a   Ali, Lobna Abo ^a   Alm El Din, Rasha A ^a   Hasby, Eman ^a   Shahbah, Abeer ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Gene polymorphism; HCV; IL 10; Pegylated interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERLEUKIN 10; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EGYPT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERLEUKIN 10 GENE; MALE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE;

HEPATITIS C VIRUS;

EID: 84900347249     PISSN: 11108630     EISSN: 20902441     Source Type: Journal    
DOI: 10.1016/j.ejmhg.2013.03.006     Document Type: Article

References (38)

1. Akkaya O., Kiyici M., Yilmaz Y., et al. Clinical significance fo activity of ALT enzyme in patients with hepatitis C virus. World J Gastroenterol 2007, 13:5481.
2. Constatntini P.K., Wawrezynowicz M., Clare M., et al. Interleukin-1, Interleukin-10 and tumour necrosis factor alpha gene polymorphism in hepatitis C virus infection; An investigation of the relationship with spontaneous viral clearance and response to alpha interferon therapy. Liver 2002, 22:404.
3. Hohler T., Kruger A., Gerken G., et al. Tumour necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998, 54:173.
4. Zein N.N., Germer J.J., El-Zayadi A.R., et al. Ethnic differences in polymorphism of tumour necrosis factor alpha, interleukin-10 and transforming growth factor beta gene in patients with chronic hepatitis C virus infection. Am J Trop Med Hyg 2004, 70:434.
5. Minton Elizabeth J., David S., Paula S., et al. Clearance of hepatitis C virus is not associated single nucleotide polymorphism in the IL-1 -6 or -10 genes. Hum Immunol 2005, 66:127.
6. Tzy-Yen C., Yih-Shou H., Wu Triang Tiau, et al. Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. J Lab Clin Med 2007, 150:116.
7. Govan V.A., Constant D., Hoffman M., et al. The allelic distribution of 308 tumour necrosis factor alpha gene polymorphism in south African woman with cervical cancer and control women. BMC Cancer 2006, 24.
8. Bidwell L., Keen I., Gallagher G., et al. Cytokine gene polymorphism in human disease: on line database. Genes Immune 1999, 1:3.
9. Nelson D.R., Lauwer J.Y., Lau J.Y.N., et al. Interlekin-10 treatment reduce fibrosis in patients with chronic hepatitis C: a pilot trial of interferon on responders. Gastroenterology 2000, 118:655.
10. Lio D., Caruso C., Distefano R., et al. IL-10 and TNF alpha polymorphism and the recovery from HCV infection. Hum immunol 2003, 64:674.
11. Brass V., Bieck E., Montserret R., Wolk B., Hellings J.A., et al. An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J Biol Chem 2002, 277:8130-8139.
12. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. METAVIR Cooperat Study Group Hepatol 1996, 24:289-293.
13. Oleksyk T.K., Thio C.L., Truelove A.L., et al. Single nucleotide polymorphism and haplotype in the IL-10 region associated with HCV clearance. Genes Immun 2005, 6:347.
14. Paladino N., Fainboim H., Theiler G., et al. Gender susceptibility to chronic gepatitis C virus infection associated with interleukin 10 promotor polymorphism. J Virol 2006, 80:9144.
15. Edwards-Smith C.J., Jonsson J.R., Purdie D.M., et al. Interleukin-10 promotor polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999, 30:526.
16. Mangia A., Santoro R., Piattelli M., et al. IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokine 2004, 25:103.
17. Yoneda S., Umemura T., Katasoyama Y., et al. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J Infect Dis 2011, 14:1.
18. Shaker O.G., Sadik N.A. Polymorphism in interleukin-10 and interleukin-28 B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin- therapy. J Gastroenterol Hepatol 2012, 27:1842.
19. Kakumu S., Okumura A., Ishikawa T., et al. Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha receptors in type C chronic liver disease. Clin Exp Immunol 1997, 109:458.
20. Inglot M., Gladysz A., Rymer W., et al. Cytokine assessment in untreated hepatitis C virus infected patients and during interferon alpha + ribavirin therapy. Wiad Lek 2008, 61:13.
21. Marcello C.B., Valenti M., Bertino G., et al. Relationship between circulating interleukin-10 and histological features in patients with chronic C hepatitis. Ann Saudi Med 2011, 31(4):360.
22. Wan I., Kung Y.I., Lin Y.I., et al. Th1 and Th2 cytokines are elevated in HCV- infected SVR (-) patients treated with interferon alpha. Biochem Biophys Res Commun 2009, 379:855.
23. Kuzushita N., Hayashi N., Katayama K., et al. High levelas of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Scand J Gastroenterol 1997, 32:169.
24. Marin-Serrano E., Rodriguez-Ramos C., Diaz F., et al. Modulation of the anti-inflammatory interleukin-10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. J Viral Hepat 2006, 13:230.
25. Umemura T., Zen Y., Schechterly C., et al. Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C. Hepatology 2006, 43:91.
26. Takaki A., Wiese M., Maertens G., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000, 6:578.
27. Tanaka Y., Nishida N., Sugiyama M., et al. Genome-wide association of IL-28 B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105.
28. Manesis E.K., Papaioannou C., Kaferi G., et al. Biochamical and virological outcome of patients with chronic hepatitis C with interferon alpha 2 b for 6 or 12 months: A 4 year follow up of 211 patients. Hepatology 1997, 26(3):734.
29. Lin C.S., Chang C.S., Yeh H.Z., et al. Retrtspective evaluation of serum markersAPRI and AST/ALT for assissing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma. Intern Med 2008, 47:569.
30. Brook D.G., Trifilo M.J., Edelmann K.H., et al. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006, 12:1301.
31. Ejrnaes M., Filippi C.M., Martinic M.M., et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 2006, 203:2461.
32. Naslednikoya I.Q., Konencov V.I., Ryazantseva N.V., et al. Role of genetically determined production of immunoregulatory cytokines in immunopathogenesis of chronic viral hepatitis. Bull Exp Biol Med 2007, 143:706.
33. Chuang J.Y., Yang S.S., Lu Y.T., et al. IL-10 promotor gene polymorphism and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Dig Liver Dis 2009, 41:424.
34. Abbott W.C., Rigopoulou E., Haigh P., et al. Single nucleotide polymorphism in the interferon gamma and interleukin-10 genes do not influence chronic hepatitis C severity or T-cell reactivity to hepatitis C virus. Liver Int 2004, 24:90.
35. Knapp S., Branwen J.W., Hennig A.J., et al. Interleukin-10 promotor polymorphism and the outcome of hepatitis C virus infection. Immunogenetics 2003, 55(6):362.
36. Dogra G., Chakravarti A., Kar P., et al. Polymorphism of tumor necrosis factor alpha and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon alpha therapy response. Hum Immunol 2011, 72:935.
37. Selzner N., McGilvray I. Can genetic variations predict HCV treatment outcome ?. J Hepatol 2008, 49:494.
38. Kurbanoy F., Abde-Hamid M., Latanich R., et al. Genetic polymorphism in IL-28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort. J Infect Dis 2011, 204:1391.